Premium
Vaccine‐induced immune thrombotic thrombocytopenia after vaccination against Covid‐19: A clinical dilemma for clinicians and patients
Author(s) -
Mohseni Afshar Zeinab,
Babazadeh Arefeh,
Janbakhsh Alireza,
Afsharian Mandana,
Saleki Kiarash,
Barary Mohammad,
Ebrahimpour Soheil
Publication year - 2022
Publication title -
reviews in medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.06
H-Index - 90
eISSN - 1099-1654
pISSN - 1052-9276
DOI - 10.1002/rmv.2273
Subject(s) - vaccination , medicine , pandemic , covid-19 , immunology , intensive care medicine , public health , disease , infectious disease (medical specialty) , pathology
Summary The coronavirus disease 2019 (Covid‐19) pandemic has had devastating effects on public health worldwide, but the deployment of vaccines for Covid‐19 protection has helped control the spread of SARS Coronavirus 2 (SARS‐CoV‐2) infection where they are available. The common side effects reported following Covid‐19 vaccination were mostly self‐restricted local reactions that resolved quickly. Nevertheless, rare vaccine‐induced immune thrombotic thrombocytopenia (VITT) cases have been reported in some people being vaccinated against Covid‐19. This review summarizes the thromboembolic events after Covid‐19 vaccination and discusses its molecular mechanism, incidence rate, clinical manifestations and differential diagnosis. Then, a step‐by‐step algorithm for diagnosing such events, along with a management plan, are presented. In conclusion, considering the likeliness of acquiring severe SARS‐CoV‐2 infection and its subsequent morbidity and mortality, the benefits of vaccination outweigh its risks. Hence, if not already initiated, all governments should begin an effective and fast public vaccination plan to overcome this pandemic.